by 40 mg to the MTD in groups of 3 patients. DDP (80 mg/m 2 ) was begun on Day ogy/Oncology, Hollings Cancer Center, Medical 2 and repeated weekly for a total of 3 weeks. During Week 4, the patients were University of South Carolina, Charleston, South not treated with DDP but instead evaluated for r
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma
β Scribed by Edward T. Creagan; James N. Ingle; David L. Ahmann; Stephanie J. Green
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 206 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.
Cancer 49:1353-1354. 1982.
NDOCRINE FACTORS may have some influence on
π SIMILAR VOLUMES
Eighteen patients with surgically incurable metastatic malignant melanoma were treated with a mixture of irradiated (15,000 rads) autologous tumors cells (1-2 X 10(8)) and BCG (Glaxo, 2-4.5 X 10(6) organisms), which was injected intradermally (in five divided doses) every 2 weeks (X5). Four of 18 (2
Department of Heremission whereas 5 patients (23%) succumbed to early death and 3 patients (14%) matology and Oncology, Go Β¨ttingen, Germany. did not respond. Blood counts recovered at a median of 33.5 days after the start 2 Westfa Β¨lische Wilhelms University, Department of treatment and complete r